Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in atherosclerosis with type 2 diabetes mellitus or impaired glucose tolerance
2009-014618-80Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerosis comparing Canakinumab with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on 2009-014618-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014618-80.